1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Strategy

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+

 
• By Malcolm Spicer

A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.

ChromaDex rolled out Rx nicotinamide adenine dinucleotide products in August, along with a test kit for providers and consumers. (Source: CHromaDex)
Key Takeaways
  • Firm said its corporate name will be Niagen Bioscience Inc. starting on 19 March

ChromaDex Corp. is changing its name to better reflect its transition from relying on revenues from nicotinamide adenine dinucleotide (NAD+)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

DSM-Firmenich Sees Innovation Opportunities For Dietary Supplements

 
• By Tom Gallen

The global ingredients supplier has recently launched microbiome-focused products to expand its supplements offering and has more innovations in the pipeline.

Expanded Distribution In US Helps Drive Up BioGaia Sales

 
• By Tom Gallen

Swedish probiotics player BioGaia is reaping the benefits of increased marketing investments and distribution in the US.

Over The Counter: Seizing The Healthy Aging Opportunity, With Prime Fifty’s Max Gowland

 
• By David Ridley

HBW Insight speaks to Prime Fifty founder and managing director Max Gowland about the science behind healthy aging and the opportunity for the consumer health industry.

Nestlé Puts VMS Value Brands On Chopping Block To Focus On Premium Market

 
• By Tom Gallen

Nature’s Bounty, Osteo Bi-Flex and Puritan’s Pride are among the dietary supplement brands under strategic review by Nestle as the firm shifts its focus to the premium end of the market.

More from HBW Insight

‘Classic Economic Injury’ Merits Plaintiffs’ Standing In Challenge To US FDA Homeopathic Regulation

 
• By Malcolm Spicer

Attorney Jonathan Emord says federal court’s grant of standing for Alliance for Natural Health USA and Meditrend to challenge FDA’s safety concerns about homeopathic drugs leaves open a door to continue arguing the agency violated multiple regulations by imposing NDA requirements for homeopathics.

Producers Sue Oregon Over ‘Crushing’ EPR Recycling Law, Call It Unconstitutional

 
• By Eileen Francis

A national wholesalers’ trade group is suing Oregon, claiming its EPR law, which requires producers to register, report packaging data and pay fees, is unconstitutional and overly burdensome.

FDA RIF Delays Response On NPA NMN Petition

 
• By Malcolm Spicer

Due to staff reductions at FDA ordered by DOGE, but accounting for return of some employees after their dismissals were rescinded, agency missed July 31 deadline it had set for responding to the NPA’s petition and expects to respond by Sept. 30.